Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>

18 Jun 2015

Abstract excerpt

PURPOSE: Ibrutinib leads to a transient lymphocytosis in patients with chronic lymphocytic leukemia (CLL) that develops within hours of starting drug and is due to the efflux of cells from lymphoid tissues into the blood. We therefore sought to investigate the in vivo effect of ibrutinib on migration and adhesion of CLL cells. EXPERIMENTAL DESIGN: Patients received single-agent ibrutinib (420 mg daily) on an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Galectins and Cancer Biology
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26089373
DOI: 10.1158/1078-0432.ccr-15-0781

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <i>In Vivo</i>PMID 26089373Read ↗

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical ModelsSemantic proximity Read ↗

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.Semantic proximity Read ↗

Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.Semantic proximity Read ↗

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathwaysSemantic proximity Read ↗

Detection of Emerging Ibrutinib Resistance by Flow Cytometry in Patients with Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.Semantic proximity Read ↗

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progressionSemantic proximity Read ↗

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.Semantic proximity Read ↗

Adhesion molecules expression in CLL: Potential impact on clinical and hematological parameters.Semantic proximity Read ↗

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.Semantic proximity Read ↗

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Bruton’s tyrosine kinase (BTK) regulates myeloid cell recruitment during acute inflammationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.